Mardi Dier - Dec 2, 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
EVP and CFO
Signature
/s/ Mardi Dier
Stock symbol
MDGL
Transactions as of
Dec 2, 2025
Transactions value $
-$1,363,364
Form type
4
Date filed
12/3/2025, 05:59 PM
Previous filing
Jun 13, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dier Mardi EVP and CFO C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN /s/ Mardi Dier 2025-12-03 0001574591

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Options Exercise $1.05M +4.17K +39.97% $251.63 14.6K Dec 2, 2025 Direct
transaction MDGL Common Stock Sale -$183K -320 -2.19% $570.39 14.3K Dec 2, 2025 Direct F1, F2
transaction MDGL Common Stock Sale -$235K -410 -2.87% $571.99 13.9K Dec 2, 2025 Direct F1, F3
transaction MDGL Common Stock Sale -$203K -354 -2.55% $573.02 13.5K Dec 2, 2025 Direct F1, F4
transaction MDGL Common Stock Sale -$412K -717 -5.3% $574.00 12.8K Dec 2, 2025 Direct F1, F5
transaction MDGL Common Stock Sale -$69K -120 -0.94% $574.95 12.7K Dec 2, 2025 Direct F1, F6
transaction MDGL Common Stock Sale -$138K -240 -1.89% $576.15 12.5K Dec 2, 2025 Direct F1, F7
transaction MDGL Common Stock Sale -$185K -320 -2.57% $577.81 12.1K Dec 2, 2025 Direct F1, F8
transaction MDGL Common Stock Sale -$149K -258 -2.13% $578.83 11.9K Dec 2, 2025 Direct F1, F9
transaction MDGL Common Stock Sale -$278K -480 -4.04% $579.85 11.4K Dec 2, 2025 Direct F1, F10
transaction MDGL Common Stock Sale -$141K -240 -2.11% $585.44 11.2K Dec 2, 2025 Direct F1, F11
transaction MDGL Common Stock Sale -$141K -240 -2.15% $587.85 10.9K Dec 2, 2025 Direct F1, F12
transaction MDGL Common Stock Sale -$94.3K -160 -1.47% $589.65 10.8K Dec 2, 2025 Direct F1, F13
transaction MDGL Common Stock Sale -$94.5K -160 -1.49% $590.37 10.6K Dec 2, 2025 Direct F1, F14
transaction MDGL Common Stock Sale -$44K -74 -0.7% $595.20 10.5K Dec 2, 2025 Direct F1, F15
transaction MDGL Common Stock Sale -$47.7K -80 -0.76% $596.19 10.4K Dec 2, 2025 Direct F1, F16

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -4.17K -31.25% $0.00 9.18K Dec 2, 2025 Common Stock 4.17K $251.63 Direct F17
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.17 to $570.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.45 to $572.34, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.48 to $573.38, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.59 to $574.44, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.67 to $575.24, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.69 to $576.46, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.36 to $578.31, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $578.37 to $579.20, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.59 to $580.46, inclusive.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.08 to $585.99, inclusive.
F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.58 to $588.07, inclusive.
F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.13 to $589.96, inclusive.
F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.15 to $590.58, inclusive.
F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $595.18 to $595.41, inclusive.
F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $596.18 to $596.19, inclusive.
F17 All shares issued pursuant to the exercise of the options reported herein represent 4,173 shares underlying an overall option award of 13,353 shares. All exercised options had vested. As to the overall option for 13,353 shares, 25% of the shares vested on March 1, 2025, and, thereafter, 6.25% of the shares vested or will vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.